“The ₹10,000 crore allocation under Biopharma Shakti reflects a clear recognition that India’s biopharma ambitions will be shaped not only by manufacturing scale, but by the strength of its clinical and regulatory foundations. The plan to create over 1,000 accredited clinical trial sites and strengthen regulatory review is a key step toward improving the quality and credibility of clinical research, especially as biologics and biosimilars become more important in treating diseases such as cancer, diabetes and autoimmune disorders.
The budget also highlights artificial intelligence as a national priority and proposes the creation of five regional medical hubs that integrate care, diagnostics and research. Together, these measures point to a more connected healthcare system where reliable clinical and diagnostic data will be essential.
For Qure.ai, this direction reinforces the need to build diagnostic and data systems that work reliably at scale and support India’s credibility in global biopharma research, without adding complexity to already stretched health systems.”
- Advertisement -
